Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC)
Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir N, Alba E, Im SA, Janni W, Chandiwana D, Lanoue B, Thuerigen A, Gaur A, Harbeck N (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S350-S351
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2020.08.378
Authors with CRIS profile
Involved external institutions
Massachusetts General Hospital
United States (USA) (US)
Breast Cancer Research Centre-Western Australia
Australia (AU)
University of Liège (ULg) / Université de Liège
Belgium (BE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Novartis AG
Switzerland (CH)
Seoul National University (SNU) / 서울대학교
Korea, Republic of (KR)
Universitätsklinikum Ulm
Germany (DE)
Hospital Universitario Virgen de la Victoria
Spain (ES)
American University of Beirut (AUB) / الجامعة الأميركية في بيروت
Lebanon (LB)
United States (USA) (US)
Breast Cancer Research Centre-Western Australia
Australia (AU)
University of Liège (ULg) / Université de Liège
Belgium (BE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Novartis AG
Switzerland (CH)
Seoul National University (SNU) / 서울대학교
Korea, Republic of (KR)
Universitätsklinikum Ulm
Germany (DE)
Hospital Universitario Virgen de la Victoria
Spain (ES)
American University of Beirut (AUB) / الجامعة الأميركية في بيروت
Lebanon (LB)
How to cite
APA:
Fasching, P., Bardia, A., Nusch, A., Jerusalem, G., Chan, A., El Saghir, N.,... Harbeck, N. (2020). Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC). In ANNALS OF ONCOLOGY (pp. S350-S351). AMSTERDAM: ELSEVIER.
MLA:
Fasching, Peter, et al. "Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC)." Proceedings of the ESMO Virtual Congress AMSTERDAM: ELSEVIER, 2020. S350-S351.
BibTeX: Download